Sangoma Technologies (NASDAQ:SANG – Get Free Report) and Avalon GloboCare (NASDAQ:CHGA – Get Free Report) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Analyst Ratings
This is a summary of current ratings for Sangoma Technologies and Avalon GloboCare, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sangoma Technologies | 2 | 2 | 1 | 0 | 1.80 |
| Avalon GloboCare | 1 | 0 | 0 | 0 | 1.00 |
Sangoma Technologies presently has a consensus price target of $4.00, indicating a potential downside of 11.31%. Given Sangoma Technologies’ stronger consensus rating and higher probable upside, equities analysts plainly believe Sangoma Technologies is more favorable than Avalon GloboCare.
Risk and Volatility
Sangoma Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500.
Insider & Institutional Ownership
39.7% of Sangoma Technologies shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 16.8% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Sangoma Technologies and Avalon GloboCare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sangoma Technologies | -38.99% | -3.85% | -2.93% |
| Avalon GloboCare | N/A | N/A | -53.69% |
Valuation & Earnings
This table compares Sangoma Technologies and Avalon GloboCare”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sangoma Technologies | $200.06 million | 0.75 | -$81.09 million | ($2.39) | -1.89 |
| Avalon GloboCare | $1.26 million | 0.81 | -$18.26 million | ($13.80) | -0.07 |
Avalon GloboCare has lower revenue, but higher earnings than Sangoma Technologies. Sangoma Technologies is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
Summary
Sangoma Technologies beats Avalon GloboCare on 8 of the 14 factors compared between the two stocks.
About Sangoma Technologies
Sangoma Technologies Corporation develops, manufactures, distributes, and supports voice and data connectivity components for software-based communication applications worldwide. The company offers Switchvox, a voice over internet protocol phone system; Switchvox Cloud, a unified communications solution, as well as provides cloud communication solutions. It offers SIP Trunking, a telephone service for one or multiple locations; PBXact Cloud, a centralized internet based solution; Asterisk and FreePBX, an open source IP PBX software; and FAXStation, a fax-over-IP solution. In addition, the company provides desk phone, DECT phones, and headset related products. Further, it offers VoIP gateways, session border controllers, telephony card, and managed service provider services. Sangoma Technologies Corporation was founded in 1984 and is headquartered in Markham, Canada.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Receive News & Ratings for Sangoma Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangoma Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
